TABLE 6

In vitro activities of clinical CoNS isolates toward newer antibiotic agents

ParameterValue or description in study for given species a
von Eiff et al., 2005 (500) Kratzer et al., 2007 (525) Hellmark et al., 2009 (499) Karlowsky et al., 2011 (501, 526)
MS-SEMR-SEMS-SHMR-SHMS-SEMR-SES. epidermidisMS-SEMR-SE
Study design parameters
    No. of isolates1421171515873383 (501), 202 (526)19 (501), 34 (526)
    CountryGermanyGermanyGermanyGermanyAustriaAustriaSwedenCanadaCanada
    SourceDiverseDiverseDiverseDiverseBSI of BMTRsBSI of BMTRsPJIDiverseDiverse
MIC90, MIC range
    CeftarolineNDNDNDNDNDNDND0.25, ≤0.12–0.50.5, 0.25–1
    Ceftobiprole0.5, 0.13–12, 0.5–40.5, 0.13–14, 1–4NDND1.5, 0.094–1.51.0, ≤0.06–22, 1–4
    Linezolid1.0, 0.5–11, 0.5–11, 0.5–11, 0.5–1NDND0.25, 0.047–0.381, ≤0.12–2 (501), and 1, ≤0.12–2 (526)1, 0.5–1 (501), and 1, 0.25–1 (526)
    DaptomycinNDNDNDND0.25, <0.01–0.250.25, <0.01–0.5ND0.25, ≤0.03–0.25 (501), and 0.25, ≤0.03–1 (526)0.25, 0.12–0.25 (501), and 0.25, 0.12–0.5 (526)
    TigecyclineNDNDNDND0.5, 0.06–0.50.5, <0.01–0.50.25, 0.047–0.50.5, ≤0.03–0.5 (501), and 0.5, ≤0.03–0.5 (526)0.25, 0.06–0.25 (501), and 0.25, 0.06–0.5 (526)
    DalbavancinNDNDNDNDNDND0.047, 0.003–0.0470.06, ≤0.03–10.06, ≤0.03–0.06
    TelavancinNDNDNDNDNDNDND0.5, ≤0.06–10.5, 0.12–1
  • a Abbreviations: ND, not done; SE, S. epidermidis; SH, S. haemolyticus; MS, methicillin susceptible; MR, methicillin resistant; PJI, prosthetic joint infection; BMTRs, bone marrow transplant recipients; BSI, bloodstream-related infection.